These results suggest that NUCB2 may serve not only as a marker of spatial heterogeneity within GBM but also as a potential prognostic biomarker, highlighting the critical importance of region‐specific molecular characterisation in elucidating GBM pathobiology and progression dynamics. Here, NUCB2 is linked to glioblastoma.